Symbol="ITOS"
AssetType="Common Stock"
Name="Iteos TherapeuticsÂ Inc"
Description="Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of immuno-oncology therapies for patients. The company is headquartered in Cambridge, Massachusetts."
CIK="1808865"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="494612000"
EBITDA="-17311000"
PERatio="46.1"
PEGRatio="None"
BookValue="18.24"
DividendPerShare="0"
DividendYield="0"
EPS="0.3"
RevenuePerShareTTM="3.586"
ProfitMargin="0.0902"
OperatingMarginTTM="-0.142"
ReturnOnAssetsTTM="-0.0144"
ReturnOnEquityTTM="0.018"
RevenueTTM="127703000"
GrossProfitTTM="267630000"
DilutedEPSTTM="0.3"
QuarterlyEarningsGrowthYOY="-0.886"
QuarterlyRevenueGrowthYOY="-0.917"
AnalystTargetPrice="42.25"
TrailingPE="46.1"
ForwardPE="12.56"
PriceToSalesRatioTTM="1.681"
PriceToBookRatio="1.187"
EVToRevenue="0.0111"
EVToEBITDA="0.0154"
Beta="1.161"
num_52WeekHigh="28.05"
num_52WeekLow="12.52"
num_50DayMovingAverage="14.39"
num_200DayMovingAverage="17.2"
SharesOutstanding="35763700"
DividendDate="None"
ExDividendDate="None"
symbol="ITOS"
open="14.02"
high="14.40"
low="13.90"
price="14.23"
volume="144934.00"
latest_trading_day="2023-07-12"
previous_close="13.83"
change="0.40"
change_percent="2.8923%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="69"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="31"
Volume_recent_avg="283150"
Change_recent_avg="-0.06"
Delta_recent_avg="0.74"
Variance_recent_avg="0.37"
Change_ratio_recent_avg="-0.44"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="31"
Aroon_momentum_negative="69"
image_negative_thumbnail_id_1="520"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_negative_thumbnail_id_2="1130"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0163.jpeg"
image_neutral_thumbnail_id_1="576"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0023.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="616"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0092.jpeg"
image_positive_thumbnail_id_2="1004"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0166.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
